Apellis Pharmactdl 0001 Stock Shares Outstanding

1JK Stock  EUR 31.28  0.82  2.55%   
APELLIS PHARMACTDL 0001 fundamentals help investors to digest information that contributes to APELLIS PHARMACTDL's financial success or failures. It also enables traders to predict the movement of APELLIS Stock. The fundamental analysis module provides a way to measure APELLIS PHARMACTDL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to APELLIS PHARMACTDL stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

APELLIS PHARMACTDL 0001 Company Shares Outstanding Analysis

APELLIS PHARMACTDL's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current APELLIS PHARMACTDL Shares Outstanding

    
  110.58 M  
Most of APELLIS PHARMACTDL's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, APELLIS PHARMACTDL 0001 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, APELLIS PHARMACTDL 0001 has 110.58 M of shares currently outstending. This is 38.75% lower than that of the Healthcare sector and 3.48% higher than that of the Biotechnology industry. The shares outstanding for all Germany stocks is 80.66% higher than that of the company.

APELLIS Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses APELLIS PHARMACTDL's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of APELLIS PHARMACTDL could also be used in its relative valuation, which is a method of valuing APELLIS PHARMACTDL by comparing valuation metrics of similar companies.
APELLIS PHARMACTDL is currently under evaluation in shares outstanding category among its peers.

APELLIS Fundamentals

About APELLIS PHARMACTDL Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze APELLIS PHARMACTDL 0001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of APELLIS PHARMACTDL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of APELLIS PHARMACTDL 0001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in APELLIS Stock

APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.